

Supplementary Table S1. Clinical characteristic of patients with leukemia.

pt #	Sex/Age (yrs)	FAB category	Sample	WBC counts($10^9/L$)	Blast (%)	Genetic abnormalities	FIt-3 mutation status	Clinical treatment status
1	F/26	ALL2	PB	81.25	87	Bcr/Abl positive	ITD(-) D835(-)	untreated
2	M/15	ALL2	BM	165.8	87	no detection	ND	untreated
3	M/15	M5b	BM	31.99	82	no detection	ND	untreated
4	M/41	CML-CP	BM	47.44	87	Bcr/Abl positive	ND	untreated
5	M/33	ALL3	BM	24.34	93	no detection	ITD(-) D835(-)	untreated
6	F/46	M4	BM	37.6	24	no detection	ND	untreated
7	M/33	M4b	BM	122.7	41	no detection	ND	untreated
8	F/28	M3b	BM	26.41	81	no detection	ITD(-) D835(-)	untreated
9	F/45	M5b	PB	31.53	52	no detection	ND	untreated
10	M/16	CML	BM	164.3	10	no detection	ND	untreated
11	M/51	M5b	PB	19.47	78	no detection	ITD(-) D835(-)	untreated
12	M/42	M4b	BM	9.73	52	no detection	ND	untreated
13	M/52	M5a	BM	87.14	82	no detection	ND	untreated
14	M/29	M5b	PB	202	87	no detection	ITD(+) D835(-)	untreated
15	M/15	M2b	PB	15.05	37	no detection	ND	untreated
16	F/13	M2b	PB	3.5	83	no detection	ND	untreated
17	M/59	M5b	PB	3.11	35	no detection	ND	untreated
18	M/21	M3b	PB	3.42	87	PML/RAR α positive	ND	untreated
19	M/39	M3b	BM	11.52	93.5	PML/RAR α positive	ITD(+) D835(-)	untreated
20	F/38	M4b	PB	0.78	44	no detection	ND	untreated
21	F/56	M4	BM	16.9	83	no detection	ND	untreated

22	M/22	M5a	BM	75.8	77	no detection	ND	untreated
23	M/30	M5b	PB	16.69	53	no detection	ND	untreated
24	M/52	M3b	PB	44.08	90	no detection	ITD(-) D835(-)	untreated
25	M/68	M2a	PB	3.89	45.5	no detection	ND	relapse
26	F/28	M2a	PB	14.38	56	no detection	ITD(-) D835(-)	untreated
27	F/43	M4	PB	26.8	45.3	no detection	ND	untreated
28	M/71	M5b	BM	0.95	72	no detection	ITD(-) D835(-)	untreatment
29	F/19	M5b	PB	32.2	91	no detection	ITD(-) D835(-)	untreatment
30	M/8 months	M4Eo	PB	41.31	55.5	PML/RAR α (15,17), BCR/ABL t(9,22) negative	ND	untreated
31	M/11	M2	PB	16.4	91.5	AML/ETO t(8,21) 80.00%	ND	relapse
32	M/8 months	M5b	PB	77.49	88.5	MLL t(11q23) 76.00%	ITD(-) D835(-)	untreated
33	M/10	M2a	PB	4.91	26	no detection	ND	untreated
34	M/10	M5a	PB	226.67	91.5	no detection	ND	untreated
35	F/3	M5b	BM	28.3	74	CBF β MYH11 inv(16)(p13;q22), AML1/ETO t(8,21) negative	ND	untreated
36	F/1	M6	PB	19.29	22	trisomy 21 syndrome	ND	untreated
37	M/8	M2a	PB	7.31	76	no detection	ND	relapse
38	F/6	M2	BM	181	41.5	AML/ETO t(8,21) negative	ITD(-) D835(-)	untreated
39	M/4	M2b	PB	49.3	35	AML/ETO t(8,21) 90.00%	ND	untreated
40	M/7	M6	PB	5.33	21	no detection	ND	relapse
41	7months	M3a	PB	2.74	73	PML/RAR α (15:17)65%	ITD(+) D835(-)	untreated
42	F/13	M3b	PB	31.9	98	PML/RAR α (15,17)92%	ITD(-) D835(-)	untreated
43	F/21	M2	PB	3.35	78	no detection	ITD(-) D835(-)	untreated

44	M/42	AML	PB	2.56	22	no detection	ND	untreated
45	F/67	CML-BC	BM	5.93	70	46xxt(9:22)	ND	untreated
46	F/30	ALL (B Cell)	PB	99.8	87	46xy aneuploid	ITD(-) D835(-)	untreated
47	M/15	M2	PB	31.15	82	no detection	ITD(-) D835(-)	untreated
48	M/32	M2	BM	106	75.5	no detection	ND	untreated
49	F/15	ALL	PB	44.23	75.5	no detection	ND	untreated
50	F/62	M2	PB	33.06	17.5	45xx,-1,-8	ITD(-) D835(-)	untreated
51	F/28	ALL (B Cell)	PB	115.6	89	45xy,-1,-12,-5	ND	untreated
52	M/63	M4	PB	29.3	89.5	45XY,-5-9-11	ITD(-) D835(-)	untreated
53	F/27	M2	PB	67.91	85	no detection	ND	untreated
54	F/41	M4	PB	197.7	70	no detection	ND	untreated
55	F/74	M5	BM	6.75	33	45xx,-16,-21	ND	untreated
56	F/58	M1	BM	36.08	90	46xy	ITD(-) D835(-)	untreated
57	F/39	M5	PB	75.82	82.5	45xy,-11,-9,-14	ITD(-) D835(-)	untreated
58	F/4	M2	BM	354	73	45xy,-11,-9,-14	ITD(-) D835(-)	untreated
59	M/5	ALL L2 B cell	PB	4.6	60	BCR/ABL t(9 ; 22) negative	ND	untreated
60	M/7	M2a	PB	75.5	72	no detection	ND	relapse
61	M/2	ALL L2 B cell	PB	18.17	90	BCR/ABL t(9 ; 22) MLLt(11q23)TEL/AML1t(12;21)negative	ND	refractoriness
62	M/3 yr 4 months	ALL L2 B cell	PB	55	83.5	BCR/ABL t(9 ; 22) negative	ND	untreated

63	M/57	M5b	PB	1.3	44.5	no detection	ND	untreated
64	M/46	Ly+AML	PB	58.32	23	no detection	ND	untreated
65	M/17	ALL L2	PB	6.15	66	BCR/ABL t(9 ; 22) negative	ND	untreated
66	F/21	hypoplasticleukemia	PB	0.67	20	no detection	ND	untreated
67	F/67	M5b	BM	6.59	84	no detection	ND	untreated
68	F/1	M1a	PB	4.25	76	no detection	ND	untreated
69	M/34	M3a	BM	6.01	79.5	PML/RAR α positive	ND	untreated
70	M/62	M5b	PB	294.24	86	AML/ETO t(8;21) negative	ND	refractoriness
71	F/3	M2	PB	15.98	52.5	TEL/AML1 t(12;21) 82%, BCR/ABL and MLL negative	ND	untreated
72	M/15	Ly+AML	PB	61.27	92.5	no detection	ND	untreated
73	F/10	M2a	PB	4.1	60	no detection	ND	untreated
74	M/42	M5b	PB	11.18	81	no detection	ND	untreated
75	M/39	ALL-L2	PB	31.81	76	no detection	ND	untreated
76	F/36	M5b	BM	29.85	77	no detection	ND	untreated
77	F/4	M3b	PB	4.8	86	PML/RAR α positive	ND	untreated
78	M/28	M3	PB	2.35	4	PML/RAR α 21.6%	ND	untreated
79	M/44	M1	BM	286	90	no detection	ND	untreated
80	F/48	M5	PB	70.96	94	no detection	ND	untreated
81	F/36	M2a	PB	1.31	54	AML/ETO t(8;21) negative	ND	untreated

AML: acute myeloid leukemia; ALL: acute lymphoid leukemia; CML: chronic myeloid leukemia; ND: not determined.